1. Harapan H, Michie A, Mudatsir M, Sasmono RT, Imrie A. Epidemiology of dengue hemorrhagic fever in Indonesia: analysis of five decades data from the National Disease Surveillance. BMC Res Notes. 2019 Jun 20;12(1):350.
2. Kularatne SA, Dalugama C. Dengue infection: Global importance, immunopathology and management. Clin Med. 2022 Jan;22(1):9–13.
3. Heinz FX, Stiasny K. Flaviviruses and flavivirus vaccines. Vaccine. 2012 Jun 19;30(29):4301–6.
4. Sabchareon A, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Margolis HS, Letson GW. Dengue infection in children in Ratchaburi, Thailand: a cohort study. I. Epidemiology of symptomatic acute dengue infection in children, 2006-2009. PLoS Negl Trop Dis. 2012;6(7):e1732.
5. L’Azou M, Assoukpa J, Fanouillere K, Plennevaux E, Bonaparte M, Bouckenooghe A, et al. Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005–2014). Trans R Soc Trop Med Hyg. 2018 Apr;112(4):158–68.
6. Rivera, L, Biswal, S, Sáez-Llorens X, Reynales H, López-Medina E, Borja-Tabora C, et al. Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003). Oxf Univ Press Infect Dis Soc Am. 2022;75(1):107–17.
7. Vianney Tricou, Nicolas Folschweiller, Eric Lloyd, Martina Rauscher, Shibadas Biswal. Efficacy and Safety of Takeda’s Tetravalent Dengue Vaccine Candidate (TAK-003) After 4.5 Years of Follow-Up. Power Point Presentation, ICMM World Congress, 2021. https://icmmworldcongress2021.org/slides/theme1/Vianney_Tricou.pdf
8. Patel SS, Rauscher M, Kudela M, Pang H. Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine Candidate. Clin Infect Dis Off Publ Infect Dis Soc Am. 2022 May 26;76(3):e1350–9.
9. Biswal S, Reynales H, Saez-Llorens X, Lopez P, Borja-Tabora C, Kosalaraksa P, et al. Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents. N Engl J Med. 2019 Nov 21;381(21):2009–19.
10. European Medicines Agency (EMA). Assessment Report: Qdenga, Dengue Tetravalent Vaccine (Live Attenuated). EMA; 2022. (Procedure No. EMEA/H/C/005155/0000).
11. Takeda. Summary of Product Characteristics. QDENGA, Dengue Tetravalent Vaccine (Live, Attenuated). 2022.
12. Ikatan Dokter Anak Indonesia (IDAI). Jadwal Imunisasi Anak Umur 0-18 Tahun. Rekomendasi Ikatan Dokter Anak Indonesia (IDAI) Tahun 2023.
13. Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI). Jadwal Imunisasi Dewasa, Rekomendasi Satgas Imunisasi Dewasa PAPDI Tahun 2023. PAPDI, 2023.